Talic R F
Department of Surgery, College of Medicine and King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia.
Urology. 1999 Jan;53(1):106-10. doi: 10.1016/s0090-4295(98)00437-3.
Transurethral vaporization-resection of the prostate (TUVRP) is a modification of the standard transurethral prostatectomy (TURP). The technique uses the "Wing" resection loop with electrovaporization current to achieve simultaneous resection, vaporization, and coagulation of prostatic tissue. We evaluate the early safety and efficacy results of TUVRP in the treatment of patients with prostatic outflow obstruction.
The first 31 patients treated with TUVRP since September 1997 are reported. The group included 19 patients with urinary retention and 12 patients with lower urinary tract symptoms (LUTS). Patients with symptoms were assessed at baseline with the International Prostate Symptom Score (IPSS) and maximum flow rate (Qmax). The same parameters were evaluated at 3 months for the entire group. Safety parameters included changes in serum hematocrit and sodium concentration, incidence of side effects, and changes in sexual function.
All patients with retention were voiding spontaneously with an IPSS of 3.9+/-3.1 and Qmax of 21.3+/-10.2 mL/s. In the patients who presented with LUTS, the IPSS decreased from 24.3+/-8.3 to 4.1+/-4.9 at 3 months and Qmax increased from 5.2+/-4.5 mL/s to 16+/-7.5 mL/s at 3 months (P <0.001). Mean resection weight was 27.9+/-18.4 g. Mean postoperative catheter time was 24.1 hours. Mean change in hematocrit concentration was 2.5 mL/dL and the change in sodium concentration was 0.8 mEq/L. Complications included 1 patient with a bladder neck contracture, 1 with a urethral stricture, and 1 with clot retention; 1 patient developed transurethral syndrome. No change in sexual function was noted in this group.
TUVRP is a promising new modification of TURP. This procedure combines the excellent debulking capabilities of TURP (with preservation of the entire specimen for histopathologic examination) and adds the benefits of electrovaporization, resulting in minimal blood loss and electrolyte disturbance.
经尿道前列腺汽化切除术(TUVRP)是标准经尿道前列腺切除术(TURP)的一种改良术式。该技术使用带有电汽化电流的“翼形”切除环,以实现对前列腺组织的同时切除、汽化和凝固。我们评估了TUVRP治疗前列腺流出道梗阻患者的早期安全性和疗效结果。
报告了自1997年9月以来接受TUVRP治疗的首批31例患者。该组包括19例尿潴留患者和12例下尿路症状(LUTS)患者。有症状的患者在基线时采用国际前列腺症状评分(IPSS)和最大尿流率(Qmax)进行评估。整个组在3个月时评估相同参数。安全性参数包括血清血细胞比容和钠浓度的变化、副作用发生率以及性功能变化。
所有尿潴留患者均能自主排尿,IPSS为3.9±3.1,Qmax为21.3±10.2 mL/s。在出现LUTS的患者中,3个月时IPSS从24.3±8.3降至4.1±4.9,Qmax从5.2±4.5 mL/s增至16±7.5 mL/s(P<0.001)。平均切除重量为27.9±18.4 g。术后平均导尿管留置时间为24.1小时。血细胞比容浓度平均变化为2.5 mL/dL,钠浓度变化为0.8 mEq/L。并发症包括1例膀胱颈挛缩、1例尿道狭窄和1例血块潴留;1例患者发生经尿道综合征。该组未观察到性功能变化。
TUVRP是一种有前景的TURP新改良术式。该手术结合了TURP出色的减容能力(保留整个标本用于组织病理学检查),并增加了电汽化的益处,导致失血和电解质紊乱最小化。